|
1
|
Moreau ME, Garbacki N, Molinaro G, Brown
NJ, Marceau F and Adam A: The kallikrein-kinin system: current and
future pharmacological targets. J Pharmacol Sci. 99:6–38. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maeda H, Wu J, Okamoto T, Maruo K and
Akaike T: Kallikrein-kinin in infection and cancer.
Immunopharmacology. 43:115–128. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Regoli D: Pharmacology of bradykinin and
related kinins. Adv Exp Med Biol. 156:569–584. 1983.PubMed/NCBI
|
|
4
|
Marceau F and Regoli D: Bradykinin
receptor ligands: therapeutic perspectives. Nat Rev Drug Discov.
3:845–852. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lu DY, Leung YM, Huang SM and Wong KL:
Bradykinin-induced cell migration and COX-2 production mediated by
the bradykinin B1 receptor in glioma cells. J Cell Biochem.
110:141–150. 2010.PubMed/NCBI
|
|
6
|
Yu HS, Wang SW, Chang AC, et al:
Bradykinin promotes vascular endothelial growth factor expression
and increases angiogenesis in human prostate cancer cells. Biochem
Pharmacol. 87:243–253. 2014. View Article : Google Scholar
|
|
7
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar
|
|
8
|
Glimelius B and Cavalli-Bjorkman N:
Metastatic colorectal cancer: current treatment and future options
for improved survival. Medical approach - present status. Scand J
Gastroenterol. 47:296–314. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dashwood RH: Early detection and
prevention of colorectal cancer (Review). Oncol Rep. 6:277–281.
1999.PubMed/NCBI
|
|
10
|
Yoo J, Rodriguez Perez CE, Nie W,
Sinnett-Smith J and Rozengurt E: Protein kinase D1 mediates
synergistic MMP-3 expression induced by TNF-α and bradykinin in
human colonic myofibroblasts. Biochem Biophys Res Commun.
413:30–35. 2011.PubMed/NCBI
|
|
11
|
Hsieh HL, Wu CY and Yang CM: Bradykinin
induces matrix metalloproteinase-9 expression and cell migration
through a PKC-delta-dependent ERK/Elk-1 pathway in astrocytes.
Glia. 56:619–632. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
da Costa PL, Sirois P, Tannock IF and
Chammas R: The role of kinin receptors in cancer and therapeutic
opportunities. Cancer Lett. 345:27–38. 2014.PubMed/NCBI
|
|
13
|
Colman RW: Regulation of angiogenesis by
the kallikrein-kinin system. Curr Pharm Des. 12:2599–2607. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kashuba E, Bailey J, Allsup D and Cawkwell
L: The kinin-kallikrein system: physiological roles,
pathophysiology and its relationship to cancer biomarkers.
Biomarkers. 18:279–296. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Greco S, Elia MG, Muscella A, Romano S,
Storelli C and Marsigliante S: Bradykinin stimulates cell
proliferation through an extracellular-regulated kinase 1 and
2-dependent mechanism in breast cancer cells in primary culture. J
Endocrinol. 186:291–301. 2005. View Article : Google Scholar
|
|
16
|
Searovic P, Alonso M, Oses C,
Pereira-Flores K, Velarde V and Saez CG: Effect of tamoxifen and
retinoic acid on bradykinin induced proliferation in MCF-7 cells. J
Cell Biochem. 106:473–481. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ikeda Y, Hayashi I, Kamoshita E, et al:
Host stromal bradykinin B2 receptor signaling facilitates
tumor-associated angiogenesis and tumor growth. Cancer Res.
64:5178–5185. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang WH, Chang JT, Hsu SF, et al:
Bradykinin enhances cell migration in human chondrosarcoma cells
through BK receptor signaling pathways. J Cell Biochem. 109:82–92.
2010.PubMed/NCBI
|
|
19
|
Chee J, Naran A, Misso NL, Thompson PJ and
Bhoola KD: Expression of tissue and plasma kallikreins and kinin B1
and B2 receptors in lung cancer. Biol Chem. 389:1225–1233. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang W, Bhola N, Kalyankrishna S, et al:
Kinin b2 receptor mediates induction of cyclooxygenase-2 and is
overexpressed in head and neck squamous cell carcinomas. Mol Cancer
Res. 6:1946–1956. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu HS, Lin TH and Tang CH: Bradykinin
enhances cell migration in human prostate cancer cells through B2
receptor/PKCδ/c-Src dependent signaling pathway. Prostate.
73:89–100. 2013.PubMed/NCBI
|
|
22
|
Srinivasan D, Kosaka AH, Daniels DV, Ford
AP and Bhattacharya A: Pharmacological and functional
characterization of bradykinin B2 receptor in human prostate. Eur J
Pharmacol. 504:155–167. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sabatini F, Luppi F, Petecchia L, et al:
Bradykinin-induced asthmatic fibroblast/myofibroblast activities
via bradykinin B2 receptor and different MAPK pathways. Eur J
Pharmacol. 710:100–109. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee CH, Shieh DC, Tzeng CY, et al:
Bradykinin-induced IL-6 expression through bradykinin B2 receptor,
phospholipase C, protein kinase Cdelta and NF-kappaB pathway in
human synovial fibroblasts. Mol Immunol. 45:3693–3702. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sosa MS, Avivar-Valderas A, Bragado P, Wen
HC and Aguirre-Ghiso JA: ERK1/2 and p38α/β signaling in tumor cell
quiescence: opportunities to control dormant residual disease. Clin
Cancer Res. 17:5850–5857. 2011.
|
|
26
|
Tiffany CW and Burch RM: Bradykinin
stimulates tumor necrosis factor and interleukin-1 release from
macrophages. FEBS Lett. 247:189–192. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hayashi R, Yamashita N, Matsui S, et al:
Bradykinin stimulates IL-6 and IL-8 production by human lung
fibroblasts through ERK- and p38 MAPK-dependent mechanisms. Eur
Respir J. 16:452–458. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Knüpfer H and Preiss R: Serum
interleukin-6 levels in colorectal cancer patients - a summary of
published results. Int J Colorectal Dis. 25:135–140.
2010.PubMed/NCBI
|
|
29
|
Dethlefsen C, Højfeldt G and Hojman P: The
role of intratumoral and systemic IL-6 in breast cancer. Breast
Cancer Res Treat. 138:657–664. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
De Vita F, Orditura M, Auriemma A,
Infusino S, Roscigno A and Catalano G: Serum levels of
interleukin-6 as a prognostic factor in advanced non-small cell
lung cancer. Oncol Rep. 5:649–652. 1998.
|
|
31
|
Ashizawa T, Okada R, Suzuki Y, et al:
Study of interleukin-6 in the spread of colorectal cancer: the
diagnostic significance of IL-6. Acta Med Okayama. 60:325–330.
2006.PubMed/NCBI
|
|
32
|
Li R, Li G, Deng L, et al: IL-6 augments
the invasiveness of U87MG human glioblastoma multiforme cells via
up-regulation of MMP-2 and fascin-1. Oncol Rep. 23:1553–1559.
2010.PubMed/NCBI
|
|
33
|
Zheng T, Hong X, Wang J, et al: Gankyrin
promotes tumor growth and metastasis through activation of
IL-6/STAT3 signaling in human cholangiocarcinoma. Hepatology.
59:935–946. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sun W, Liu DB, Li WW, et al: Interleukin-6
promotes the migration and invasion of nasopharyngeal carcinoma
cell lines and upregulates the expression of MMP-2 and MMP-9. Int J
Oncol. 44:1551–1560. 2014.PubMed/NCBI
|
